Unlocking the Value of R&D: Managing the Risks

June 15, 2002
Martyn Postle

,
Duncan Pass

BioPharm International, BioPharm International-06-01-2002, Volume 15, Issue 6

by Duncan Pass, and Martyn Postle, Cambridge Pharma Consultancy How does big pharma look at your biotech company as a potential partner? This often depends on how it looks at its own research and development investments ? and how it presents them to shareholders. This insider's look at biotech-pharma collaboration shows you the other side of the equation.